Assessing the effect of weight and weight loss in obese persons with type 2 diabetes

被引:11
作者
Curtis, Bradley [1 ]
Hayes, Risa P. [1 ]
Fehnel, Sheri [2 ]
Zografos, Laurie [2 ]
机构
[1] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[2] RTI Hlth Solut, Res Triangle Pk, NC 27703 USA
关键词
health-related quality of life; obesity; type; 2; diabetes; weight loss; patient-reported outcomes;
D O I
10.2147/DMSO.S4237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to assess specifi c areas of life in which obesity affects individuals with type 2 diabetes mellitus (T2DM), and changes that obese persons with T2DM experience with weight loss of varying degrees. Thirty in- depth interviews were conducted in persons identifi ed as: age >= 40 years, diagnosed with T2DM for >= 2 years, on oral antihyperglycemic medications >3 months, BMI 30-35 kg/m(2), having attempted to lose weight in the last 2 years. Participants (60% female, mean age 53 years, 53% Caucasian, mean BMI 32.2 kg/ m(2)) agreed that 5% weight loss, while not refl ective of an ultimate goal, would be meaningful and important; benefi ts were expected to accrue in physical functioning, self-confi dence, blood glucose levels, and motivation to keep losing weight. Participants reported the greatest effect of weight loss on energy, physical activity, mobility, pain, and clothes/appearance. Participants reported weight affecting mood, with feelings of depression and frustration most commonly described. This research indicates that weight loss is likely to affect health-related quality of life in obese individuals with T2DM. Given the purported weight loss benefi ts of many emerging diabetic medications, it will be important to include measures of weight-related quality of life in future clinical trials of these agents.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 21 条
[1]   Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54
[2]   Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes [J].
Buse, JB ;
Henry, RR ;
Han, J ;
Kim, DD ;
Fineman, MS ;
Baron, AD .
DIABETES CARE, 2004, 27 (11) :2628-2635
[3]  
Cox D, 2002, INT J CLIN PRACT, P20
[4]   Weight loss and quality of life improvement in obese subjects treated with sibutramine: A double-blind tandomized multicenter study [J].
Di Francesco, V. ;
Sacco, T. ;
Zamboni, M. ;
Bissoli, L. ;
Zoico, E. ;
Mazzali, G. ;
Minniti, A. ;
Salanitri, T. ;
Cancelli, F. ;
Bosello, O. .
ANNALS OF NUTRITION AND METABOLISM, 2007, 51 (01) :75-81
[5]   Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors [J].
Ford, ES ;
Mokdad, AH ;
Giles, WH ;
Galuska, DA ;
Serdula, MK .
OBESITY RESEARCH, 2005, 13 (01) :118-122
[6]  
Grbich C., 2013, QUALITATIVE DATA ANA
[7]   The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes [J].
Harder, H ;
Nielsen, L ;
Thi, TDT ;
Astrup, A .
DIABETES CARE, 2004, 27 (08) :1915-1921
[8]  
Hayes RP, 2006, DIABETES ED, V32, P1
[9]   Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes [J].
Kim, Dennis ;
MacConell, Leigh ;
Zhuang, Dongliang ;
Kothare, Prajakti A. ;
Trautmann, Michael ;
Fineman, Mark ;
Taylor, Kristin .
DIABETES CARE, 2007, 30 (06) :1487-1493
[10]   The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes [J].
King, P ;
Peacock, I ;
Donnelly, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (05) :643-648